New hope for ruptured liver cancer: drug combo aims to stop recurrence
NCT ID NCT07331883
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether two drugs, sintilimab and bevacizumab, given after surgery can prevent cancer from coming back in people with ruptured liver cancer. About 35 participants will receive the combination every three weeks. The goal is to see if this approach is safe and improves how long people live without their cancer returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab and bevacizumab biosimilar
What this could lead to
If this works, it could provide a new treatment option to lower the risk of cancer returning after surgery for ruptured liver cancer.
What could go wrong
This is a small, early-phase study with only 35 participants and no comparison group. The combination may cause side effects and might not prove effective in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sanming First Hospital
NOT_YET_RECRUITINGSanming, Fujian, 365000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Third Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130033, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact